IgA Nephropathy clinical trials at UCLA
3 in progress, 2 open to eligible people
Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.
Los Angeles, California and other locations
Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
open to eligible people ages 18 years and up
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
Los Angeles, California and other locations
LNP023 in Primary IgA Nephropathy Patients
Sorry, in progress, not accepting new patients
The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.
Los Angeles, California and other locations
Our lead scientists for IgA Nephropathy research studies include Mrinalini Sarkar, MD Anjay Rastogi, MD, PhD.
Last updated: